Skip to main content

/ Technology/ Group items tagged #esmo_2019_dates

Group items tagged

Filter: All | Bookmarks | Topics Simple Middle

ESMO 2019: Samsung Bioepis reveals Bevacizumab biosimilar trial result - 1 views

www.clinicaltrialsarena.com/...samsung-bevacizumab-biosimilar

#esmo_2019 #Samsung_Bioepis_reveals # esmo_2019_dates #Bevacizumab #biosimilar_trial_result #non_small_cell_lung_cancer.

shared by jacob logan on 03 Oct 19 - No Cached

jacob logan on 03 Oct 19

A Phase 3 study comparing Samsung Bioepis' SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).

<div class="cArrow"> </div><div class="cContentInner">A Phase 3 study comparing Samsung Bioepis' SB8 with Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) demonstrated equivalent efficacy in terms of risk ratio of overall response rate (ORR).</div>

...

Cancel

ESMO 2019: Merck unveils neoadjuvant/adjuvant TNBC trial results - 1 views

www.clinicaltrialsarena.com/...nt-adjuvant-tnbc-trial-results

#esmo_2019 #Samsung_Bioepis_reveals #esmo_2019_dates #Bevacizumab #biosimilar_trial_result #non_small_cell_lung_cancer.

shared by jacob logan on 04 Oct 19 - No Cached

jacob logan on 04 Oct 19

A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.

<div class="cArrow"> </div><div class="cContentInner"> A regimen of neoadjuvant Keytruda and chemotherapy extended pathological complete response (pCR) rates by 13.6% compared to chemotherapy alone in patients with early triple-negative breast cancer (TNBC), according to findings from the Phase III Keynote-522 study presented at the ESMO Congress 2019.</div>

...

Cancel

ESMO 2019: Seven promising liquid biopsy companies at ESMO Congress - 1 views

www.medicaldevice-network.com/...o-2019-liquid-biopsy-companies

#Liquid_Biopsy #ESMO_2019 #ESMO_Congress #Medical_Device #esmo_congress_2019 #esmo_conference_2019 #esmo_2019_dates #esmo_2019_meeting

shared by jacob logan on 27 Sep 19 - No Cached

jacob logan on 27 Sep 19

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

<div class="cArrow"> </div><div class="cContentInner">Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.</div>

...

Cancel

ESMO 2019: Kisqali shows superior overall survival in breast cancer - 1 views

www.clinicaltrialsarena.com/...esmo-novartis-kisqali

#ESMO_2019 #esmo_conference_2019 #esmo_congress_2019 #Breast_Cancer #esmo_2019_dates

shared by jacob logan on 07 Oct 19 - No Cached

jacob logan on 07 Oct 19

Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.

<div class="cArrow"> </div><div class="cContentInner">Novartis has said that Kisqali delivered superior overall survival (OS) in the Monaleesa-3 trial, demonstrating more life for postmenopausal human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients.</div>

...

Cancel

1 - 4 of 4

Showing 20▼ items per page

Related searches